Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels
Kyle T. Helzer(University of Wisconsin–Madison), Shuang G. Zhao(University of Wisconsin Carbone Cancer Center), Felix Y. Feng(University of Michigan), Hannah M. Krause(University of Wisconsin–Madison), Hamid Emamekhoo(University of Wisconsin Carbone Cancer Center), Andrew J. Armstrong(Duke University), Martin Sjöström(University of California, San Francisco), Kari B. Wisinski(University of Wisconsin Carbone Cancer Center), Michael Bassetti(University of Wisconsin–Madison), Himisha Beltran(Dana-Farber Cancer Institute), Marina N. Sharifi(University of Wisconsin–Madison), Nan Sethakorn(University of Chicago), Alexander W. Wyatt(University of British Columbia), Jamie M. Sperger(University of Wisconsin–Madison), Rana R. McKay(University of California San Diego), Christos E. Kyriakopoulos(Dana-Farber Cancer Institute), Grace C. Blitzer(University of Wisconsin–Madison), Amy K. Taylor(University of Wisconsin–Madison), Matthew L. Bootsma(University of Wisconsin–Madison), Ruth O’Regan(University of Wisconsin Carbone Cancer Center), David Kosoff(University of Wisconsin–Madison), Jennifer L. Schehr(University of Wisconsin–Madison), John M. Floberg(University of Wisconsin–Madison), Joshua M. Lang(University of Wisconsin–Madison), Shannon R. Reese(University of Wisconsin–Madison), Matthew R. Chrostek(Stanford University)
Cited by 9
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k